 | 
 | |
Medtronic, Inc.
In February 2011, Nile and Medtronic entered into an agreement to collaborate on the development of cenderitide. Under the terms of the agreement, Medtronic will fund and provide its drug-device expertise as Nile executes on its Phase I clinical trial to assess the pharmacokinetics and phamacodynamics of cenderitide delivered through Medtronic diabetes pump technology. In the planned clinical trial, cenderitide will be delivered to heart failure patients for up to 24 hours through continuous subcutaneous infusion.
| |
|
